DIDO1

Across TCGA pan-cancer cohorts, DIDO1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of DIDO1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where DIDO1 RNA is repressed in tumor relative to normal tissue. In most cancer types DIDO1 is over-expressed in tumor, although a few such as THCA and UCEC show the opposite, repressed pattern.

THCA, LIHC, and STAD are the cancer types where DIDO1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DIDO1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	II,III,IV	−0.627	<.001	9	view →
LIHC	Female	II,III,IV	+0.989	<.001	8	view →
STAD	All	II,III,IV	+0.818	<.001	8	view →
HNSC	All	All	+0.515	<.001	8	view →
COAD	All	All	+0.466	<.001	6	view →
CHOL	All	All	+1.904	<.001	5	view →
UCEC	All	All	−0.763	<.001	4	view →
KIRP	All	IV	+0.772	.031	2	view →
KIRC	Female	All	+0.319	.008	2	view →
ESCA	Female	All	+0.673	.018	1	view →
KICH	All	All	−0.415	.012	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

DIDO1–THCA

Open the THCA breakdown →